黄素和甲索特雷克萨特:一种有前途的组合,用于通过子通路的抑制来治疗骨肉瘤
Giulia Giliberti1, Maria Maddalena Marrapodi2, Giuseppe Di Feo2
1Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Napoli, Italy.
International journal of molecular sciences
|October 26, 2024
概括
黄素 (CUR) 与甲托雷克萨特 (MTX) 结合,显示出治疗骨髓瘤 (OS) 的前景. 这种新的方法准了刺信号通路,减少了瘤细胞的增殖和入侵,同时可能减轻化疗副作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓瘤 (OS) 是一种严重的儿科骨癌,通常用有毒化疗治疗.
- 刺 (Hh) 信号通路与OS瘤发生有关,在瘤中过度表达.
- 目前用于OS的治疗方法具有显著的急性和慢性副作用,需要更安全的替代方案.
研究的目的:
- 研究单独使用的黄素 (CUR) 和与甲索 (MTX) 结合对抗MG-63 OS细胞系的治疗潜力.
- 为了评估CUR和MTX对OS细胞中刺信号通路的影响.
- 探索OS的新治疗策略,以提高安全性.
主要方法:
- 用CUR和MTX培养和治疗MG-63骨髓瘤细胞系.
- 评估细胞增殖,细胞亡 (BAX/Bcl-2比率) 和入侵.
- 量化Hh通路组件 (PTCH1,SMO,GLI1,GLI2) 和其他信号分子 (β-Catenin,NF-kB,MMP-2,MMP-9) 的表达水平.
主要成果:
- 在OS细胞中,CUR和MTX显著增加了细胞亡和BAX/Bcl-2比率.
- 联合治疗降低了关键的Hh通路组件 (PTCH1,SMO,GLI1,GLI2),抑制了增殖,生存和入侵.
- CUR和MTX降低了β-Catenin的表达,并显示了降低NF-kB,MMP-2和MMP-9的趋势.
结论:
- 黄素在骨髓瘤治疗中显示出作为辅助剂的潜力,特别是在与甲雷克萨特结合时.
- 用CUR和MTX针对子信号通路提供了一个有希望的策略,以提高治疗结果并降低传统OS疗法的毒性.
相关概念视频
Hedgehog Signaling Pathway
7.3K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


